Arkolith/Insider Trading/SILO/Form 4

Weisblum Eric

CEO and President, DirectorSilo Pharma, Inc. (SILO) · full profile →Form 4 · filed Apr 8, 2024
Net Buying
Open-Market Buys
$2K
Open-Market Sells
$0
Net Open-Market Flow
$2K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 5, 2024Buy(P)400$2.03$812175K
Apr 4, 2024Buy(P)600$1.96$1K175K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-24-031159) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML